Sangamo Therapeutics (NASDAQ:SGMO) Receives New Coverage from Analysts at StockNews.com

Analysts at StockNews.com assumed coverage on shares of Sangamo Therapeutics (NASDAQ:SGMO) in a report released on Saturday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Several other research analysts also recently commented on SGMO. Royal Bank of Canada reissued a “sector perform” rating and issued a $2.00 price target on shares of Sangamo Therapeutics in a report on Thursday, March 14th. HC Wainwright reissued a “buy” rating and issued a $5.00 price target (up from $3.00) on shares of Sangamo Therapeutics in a report on Tuesday, March 19th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $4.93.

Sangamo Therapeutics Trading Up 2.9 %

Sangamo Therapeutics stock opened at $0.52 on Friday. Sangamo Therapeutics has a 1-year low of $0.29 and a 1-year high of $1.78. The firm has a market capitalization of $107.44 million, a price-to-earnings ratio of -0.35 and a beta of 1.39. The firm has a 50 day simple moving average of $0.77 and a 200 day simple moving average of $0.59.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings data on Wednesday, March 13th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.09). Sangamo Therapeutics had a negative net margin of 146.30% and a negative return on equity of 82.17%. The business had revenue of $2.04 million during the quarter, compared to analysts’ expectations of $8.96 million. On average, equities research analysts forecast that Sangamo Therapeutics will post -0.54 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Miracle Mile Advisors LLC purchased a new position in Sangamo Therapeutics in the third quarter worth $25,000. Vanguard Personalized Indexing Management LLC purchased a new position in Sangamo Therapeutics in the third quarter worth $26,000. Mackenzie Financial Corp grew its position in Sangamo Therapeutics by 72.4% in the fourth quarter. Mackenzie Financial Corp now owns 73,799 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 31,003 shares in the last quarter. SG Americas Securities LLC grew its position in Sangamo Therapeutics by 255.2% in the third quarter. SG Americas Securities LLC now owns 88,542 shares of the biopharmaceutical company’s stock worth $53,000 after acquiring an additional 63,612 shares in the last quarter. Finally, Golden State Equity Partners grew its position in Sangamo Therapeutics by 22.5% in the third quarter. Golden State Equity Partners now owns 166,265 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 30,500 shares in the last quarter. 56.93% of the stock is currently owned by hedge funds and other institutional investors.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.